Results of special studies with alendronate

International Journal of Clinical Practice, Supplement

Volumn , Issue 101, 1999, Pages 67-72

  Mcclung, Michael ^a  

^a OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN;

ADULT; AGED; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSE; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ALENDRONATE; BONE DENSITY; CALCITONIN; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 33749199996     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Liberman UA, Weiss SR, Broll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal women. N Engl J Med 1995; 333: 1437-1443.
2. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
3. Hosking D, Chilvers CED, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338: 485-492.
4. Chesnut CH, McClung MR, Ensrud KE et al. Alendronate treatment of the postmenopausal woman: effect of multiple doses on bone mass and bone remodeling. Am J Med 1995; 99: 144-152.
5. Garnero P, Sornay-Rendu E, Chapuy M-C et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Min Res 1996; 11: 337-349.
6. Kanis JA, Gertz BJ, Singer F et al. Rationale for the use of alendronate in osteoporosis. Osteoporos Int 1995; 5: 1-13.
7. Sato M, Grasser W, Endo N et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast structure. J Clin Invest 1991; 88: 2095-2105.
8. Stock JL, Bell NH, Chesnut CH et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997; 103: 291-297.
9. Landman JO, Hamdy NAT, Pauwels EKJ et al. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 1995; 80: 3465-3468.
10. Avorn J, Gurwitz JH. Principles of pharmacology. In: Cassel CK, Cohen G, Larsen E, Eds. Geriatric Medicine, 3rd edn. New York: Springer, 1997; 55-70.
11. Bone HG, Downs RW, Tucci JR et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 1997; 82: 265-274.
12. Adami S, Passeri M, Ortolani S et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17: 383-390.
13. Overgaard K, Hansen MA, Jensen SB et al. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556-561.
14. Kraenzlin ME, Seibel MJ, Trechsel U et al. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 1996; 58: 216-220.
15. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-1686.